NLRP3 and Nephropathy: Our findings not only revealed a novel molecular mechanism responsible for the development and progression of AAN, but also pointed out potential therapeutics for AA-induced nephropathy by targeting renal NLRP3 inflammasome activation, which is of great significance to the prevention and treatment of AAN.